Active Ingredient(s): Nelarabine
FDA Approved: * October 28, 2005
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Arranon Overview

Nelarabine, sold under the brand names Arranon (US) and Atriance (EU), is a chemotherapy medication used for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). Nelarabine is a prodrug of arabinosylguanine nucleotide triphosphate (araGTP), a type of purine nucleoside analog, which causes inhibition of DNA synthesis and cytotoxicity.[3] Pre-clinical studies suggest that T-cells are particularly sensitive to nelarabine. In Oc...

Read more Arranon Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Arranon Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 250mg/50ml (5mg/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Arranon: (2 results)

Sorted by National Drug Code
  • 0007-4401 Arranon 5 mg/ml Intravenous Injection by Glaxosmithkline LLC
  • 0078-0683 Arranon 5 mg/ml Intravenous Injection by Novartis Pharmaceuticals Corporation

Other drugs which contain Nelarabine or a similar ingredient: (1 result)